AEs have economic impact in patientswithNSCLC

AEs have economic impact in patientswithNSCLC PharmacoEconomics & Outcomes News 784, p7 - 12 Aug 2017 AEs have economic impact in patients with NSCLC Adverse events (AEs) associated with treatment of non-small cell lung cancer (NSCLC) including immunotherapies have an economic impact, according to findings of a French study published in ClinicoEconomics and Outcomes Research. Costs of grade 3 and 4 treatment-related AEs reported in ≥1% of patients with NSCLC receiving docetaxel, erlotinib, nivolumab, pembrolizumab, pemetrexed + carboplatin + bevacizumab, ramucirumab + docetaxel, or platinum-based chemotherapies, in phase III clinical trials were evaluated from a French national health insurance perspective. Overall, 24 AEs were identified. Estimated total costs varied from €46 per event to €7742 per year, and were greater than €2000 for 14 AEs. Costs were highest for immunotherapy-related type 1 diabetes mellitus (€7742 per year), and for pneumonitis, anaemia, dehydration and anorexia (€5786, €5752, €5207 and €4349 per event, respectively), and were primarily due to hospitalisation costs. "This study may be of interest for economic evaluations of new interventions in NSCLC," the authors commented. "Among the identified AEs, a majority appeared to have an important economic impact, with a management cost of at least €2,000 mainly driven by hospitalization costs," they concluded. * 2017 euros Chouaid C, et al. Cost analysis of adverse events associated with non-small cell lung cancer management in France. ClinicoEconomics and Outcomes Research : 27 Jul 2017. Available from: URL: https://doi.org/10.2147/ CEOR.S138963 803262559 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

AEs have economic impact in patientswithNSCLC

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/aes-have-economic-impact-in-patientswithnsclc-HJBgu80ihT
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4218-y
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 784, p7 - 12 Aug 2017 AEs have economic impact in patients with NSCLC Adverse events (AEs) associated with treatment of non-small cell lung cancer (NSCLC) including immunotherapies have an economic impact, according to findings of a French study published in ClinicoEconomics and Outcomes Research. Costs of grade 3 and 4 treatment-related AEs reported in ≥1% of patients with NSCLC receiving docetaxel, erlotinib, nivolumab, pembrolizumab, pemetrexed + carboplatin + bevacizumab, ramucirumab + docetaxel, or platinum-based chemotherapies, in phase III clinical trials were evaluated from a French national health insurance perspective. Overall, 24 AEs were identified. Estimated total costs varied from €46 per event to €7742 per year, and were greater than €2000 for 14 AEs. Costs were highest for immunotherapy-related type 1 diabetes mellitus (€7742 per year), and for pneumonitis, anaemia, dehydration and anorexia (€5786, €5752, €5207 and €4349 per event, respectively), and were primarily due to hospitalisation costs. "This study may be of interest for economic evaluations of new interventions in NSCLC," the authors commented. "Among the identified AEs, a majority appeared to have an important economic impact, with a management cost of at least €2,000 mainly driven by hospitalization costs," they concluded. * 2017 euros Chouaid C, et al. Cost analysis of adverse events associated with non-small cell lung cancer management in France. ClinicoEconomics and Outcomes Research : 27 Jul 2017. Available from: URL: https://doi.org/10.2147/ CEOR.S138963 803262559 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Aug 12, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from Google Scholar, PubMed
Create lists to organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off